Alzheimer disease trials in Netherlands
16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 Nov 2026. Ask the study team whether a trial fits you.
No phaseRecruitingResearch participation
InRAD Observational Study
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 50,000 worldwide
- Run by
- Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
See details and how to joinNCT07213700Registry updated 2026-11-06
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Where
- Amsterdam, 's-Hertogenbosch, Zwolle
- Age
- 60 years to 85 years
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976216EU 2025-520746-30-00Registry updated 2026-10-27
Phase 1RecruitingTrial-stage medicine
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT05231785EU 2023-508363-79-00Registry updated 2026-10-20
Phase 2RecruitingTrial-stage medicine
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
- Where
- Amsterdam, 's-Hertogenbosch, Zwolle
- Age
- 50 years to 85 years
- People
- 340 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07033494EU 2024-519190-19-00Registry updated 2026-10-20
Phase 2RecruitingTrial-stage medicine
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
This trial only enrols participants with Down syndrome
- Where
- Amsterdam
- Age
- 40 years to 55 years
- People
- 58 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07636811EU 2025-523390-42-00Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- Where
- Amsterdam, 's-Hertogenbosch, Zwolle
- Age
- 60 years to 85 years
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976203EU 2025-520747-32-00Registry updated 2026-10-08
Phase 1RecruitingTrial-stage medicine
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
- Where
- Amsterdam, 's-Hertogenbosch
- Age
- 40 years to 80 years
- People
- 50 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07214727EU 2025-522582-30-00Registry updated 2026-10-08
No phaseRecruitingResearch participation
Dominantly Inherited Alzheimer Network (DIAN)
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Washington University School of Medicine
See details and how to joinNCT00869817Registry updated 2026-10-05
Early phase 1RecruitingResearch participation
[18F]ACI-19626 PET in TDP-43 Proteinopathies
- Where
- Amsterdam
- Age
- 40 years to 70 years
- People
- 45
- Run by
- AC Immune SA
See details and how to joinNCT06891716EU 2024-513097-21-00Registry updated 2026-08-26
Phase 2/3RecruitingTrial-stage medicine
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Washington University School of Medicine
See details and how to joinNCT05552157Registry updated 2026-07-27
Phase 2/3RecruitingTrial-stage medicine
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Washington University School of Medicine
See details and how to joinNCT06647498Registry updated 2026-07-27
No phaseRecruitingResearch participation
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
- Where
- Almere Stad, Amsterdam, Haarlem, Hilversum, Leeuwarden, Purmerend, 's-Hertogenbosch, Tilburg
- Age
- 55 years and over
- People
- 550
- Run by
- Alzheimercentrum Amsterdam
See details and how to joinNCT07680335Registry updated 2026-07-02
Phase 1RecruitingTrial-stage medicine
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
- Where
- Amsterdam, 's-Hertogenbosch, Zwolle
- Age
- 18 years to 75 years
- People
- 68 worldwide
- Run by
- Denali Therapeutics Inc.
See details and how to joinNCT07328451EU 2025-523515-11-00Registry updated 2026-07-01
No phaseRecruitingResearch participation
Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
- Where
- Amsterdam
- Age
- 50 years to 85 years
- People
- 55
- Run by
- Willem de Haan
See details and how to joinNCT07036328Registry updated 2026-05-12
Phase 1/2RecruitingResearch participation
A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Efavirenz in Patients with Early Alzheimer’s Disease
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 40
- Run by
- Amsterdam UMC
See details and how to join2023-509613-37-01EU 2023-509613-37-01Registry updated 2026-02-06
Phase 2Not yet recruitingResearch participation
Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease
- Where
- Groningen
- Age
- 18 years and over
- People
- 30
- Run by
- Universitair Medisch Centrum Groningen
See details and how to join2024-518865-85-00EU 2024-518865-85-00Registry updated 2026-01-19
All Alzheimer disease trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.